NCT06814015 Self-balancing Personal Exoskeleton for SCI (Site 2)
| NCT ID | NCT06814015 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wandercraft |
| Condition | Spinal Cord Injuries (SCI) |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-03-31 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2025-03-31 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to demonstrate the safety and effectiveness of the personal exoskeleton in individuals with spinal cord injury (SCI).
Eligibility Criteria
SCI user inclusion Criteria: * Any gender, age 18 years or older; * Motor complete or incomplete SCI with lesions at or above T6; * ≥ 6 months post SCI; * Able and willing to attend 9 to 10 visits1 to the center, including sessions of training and assessments of one-to-three hours duration; * Able to read, understand, and provide informed consent; * Living in the US and speaks English. SCI user exclusion Criteria: * Diagnosis of neurological injury other than SCI; * Progressive condition that would be expected to result in changing neurological status; * Severe concurrent medical disease, illness or condition judged to be contraindicated by the site physician; * Unhealed or unstable traumatic or high impact lower extremity fracture of any duration that is, in the clinical judgement of the study physician, exclusionary for standing and walking; * Knee (proximal tibia and/or distal femur) BMD \<0.60 gm/cm2; * Total hip BMD T-scores \< -3.5; * Fragility, minimal trauma, or low impact fracture of the lower extremity since SCI; * Untreatable severe spasticity judged to be contraindicated by the site physician; * Untreated/uncontrolled hypertension, as judged to be contraindicated by the site physician; * Unresolved orthostatic hypotension (change from baseline seated BP to a fall in 20mmHg SBP and/or fall in 10mmHG DBP and symptoms when standing), or as judged to be contraindicated by the site physician; * Open or unhealed skin pressure sores, abrasions, or bruises at any of the contact points of the exoskeleton; * Morphological contraindications to the use of the device; * Uncorrectable leg length discrepancy over 2 cm (about 0.79 in) when using additional correction tools; * Unable to effectively operate the device with a hand-control interface, due to functional and/or cognitive impairment, evaluated based on the ability to manipulate the joystick in all direction, press and identify buttons on the hand control interface. * Improper fitting in the device; * Psychopathology documentation in the medical record that may conflict with study objectives; * Pregnancy or women who plan to become pregnant during the study period; * Concurrent participation in another interventional trial; * History of uncontrolled autonomic dysreflexia; * Presence colostomy and/or urostomy; * Ventilator use at the time of the exoskeleton use; * Insufficient strength and performance capability (the ability to transfer into/out of the device or perform other training tasks with assistance). Companion inclusion Criteria: * Any gender, age 18 years or older; * Willingness to attend 9 to 10 visits to the center, including sessions of training and assessments of one-to-three hours duration with the SCI user; * Able to read, understand and provide informed consent; * Living in the US and speaks English. Companion exclusion Criteria: * Inability to communicate with an assistant due to cognitive and language disorders; * Any disease, concomitant injury, or condition that interferes with the performance or interpretation of the protocol- specified assessments; * Insufficient strength and performance capability, evidenced by the ability to hold and retain the device in case of unbalance/fall; * Insufficient availability to complete the study; * Concurrent participation in another interventional trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06814015 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Spinal Cord Injuries (SCI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06814015 currently recruiting?
Yes, NCT06814015 is actively recruiting participants. Contact the research team at lmartinez@kesslerfoundation.org for enrollment information.
Where is the NCT06814015 trial being conducted?
This trial is being conducted at West Orange, United States.
Who is sponsoring the NCT06814015 clinical trial?
NCT06814015 is sponsored by Wandercraft. The trial plans to enroll 24 participants.